asco.org2 天
Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org10 天
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org2 天
LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase I study of weekly intraperitoneal paclitaxel combined with S-1 and oxaliplatin for ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...